Bicara Therapeutics Inc. Common Stock
- BCAX
- NASDAQ
- Biotechnology
- Bifunctional Antibodies
- Solid Tumor Therapy
$17.47
Today +4.11%Quote Oct 19, 2026, 08:00 PM UTC
−22.84%over the last month
Max drawdown −27.9%From 1-month high −23.3%3 months −37.9%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Bicara Therapeutics Inc. Common Stock
Bicara Therapeutics Inc., a biopharmaceutical firm in the clinical development phase, is headquartered in Boston, Massachusetts. Established in 2018, the company specializes in creating innovative, dual-action treatments specifically for solid tumors.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
103
Market value
$1.16B
Quote Oct 19
Floor
$17.15
1.8% below price
Resistance
$17.62
0.8% above price
Price vs analyst targets
9 analysts
Lowest target
$20.00Highest target
$42.00
$20.00Highest target
$42.00
- Price $17.47
- Average target $32.57
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 86% higher. Their range is wide.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BCAXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free